Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05523947 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
A Phase 1 study of HER2-Positive Solid Tumor, sponsored by Yuhan Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 147
- Enrollment target
- 19
- Study locations
NCT05523947 is a Phase 1 study of HER2-Positive Solid Tumor that is actively recruiting participants, run by Yuhan Corporation. The registered enrollment target is 147 participants. The trial reports 19 study locations across 6 states.
The verdict
NCT05523947, a Phase 1 study of HER2-Positive Solid Tumor, is actively recruiting participants, sponsored by Yuhan Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 147 participants
- Enrollment target
- 19
- Study locations
Study Summary
This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.
Conditions Studied
Interventions
- DRUG YH32367
Study Locations (19)
Other
- Southern Oncology Clinical Research Unit - Adelaide
- Austin Health - Melbourne
- Breast Cancer Research Centre - WA - Perth
- Blacktown Hospital - Sydney
- Gachon Gil University Medical Center - Incheon
- Korea University Anam Hospital - Seoul
- Seoul National University Hospital - Seoul
- Severance Hospital, Yonsei University Health System - Seoul
- Asan Medical Center - Seoul
- Samsung Medical Center - Seoul
- The Catholic University of Korea, St. Mary's hospital - Seoul
- Ulsan University Hospital - Ulsan
Gyeonggi-do
- CHA Bundang Medical Center - Seongnam-si
- Catholic University of Korea St. Vincent's Hospital - Suwon
- Ajou University Hospital - Suwon
Massachusetts
- Dana Farber Cancer Institute - Boston
Tennessee
- Vanderbilt Ingram Cancer Center - Nashville
Gyeongsangnam-do
- Gyeongsang National University Hospital - Jinju
North Chungcheong
- Chungbuk National University Hospital - Cheongju-si
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2022-08-26 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05523947
The ClinicalTrials.gov registry entry for NCT05523947 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yuhan Corporation, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HER2-Positive Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which YH32367 is the first listed.
NCT05523947 reports 19 study locations spanning 6 distinct geographic areas - top geographies include Other, Gyeonggi-do, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05523947 about?
NCT05523947 is a clinical study titled "Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor". This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.
What is the current status of trial NCT05523947?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 147 participants. The study started on 2022-08-26. Estimated completion is 2028-04-30.
What conditions does trial NCT05523947 study?
This clinical trial studies the following conditions: HER2-Positive Solid Tumor.
What interventions are being tested in trial NCT05523947?
The interventions under investigation include: YH32367 (DRUG).
Who is sponsoring clinical trial NCT05523947?
This trial is sponsored by Yuhan Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05523947 being conducted?
This trial has 19 study locations across Massachusetts, Tennessee, Gyeonggi-do, Gyeongsangnam-do, North Chungcheong. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-Positive Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.